Global Psychedelic Therapeutics Market

Report ID : 1329 | Published : 2022-07-18 | Pages: 204 | Format: PDF/EXCEL

The Global Psychedelic Therapeutics Market size was valued at US$ 3.61 Billion in 2021 and is expected to grow at a compound annual growth rate (CAGR) of 13.2% from 2022 to 2028. Psychedelic medicines are also referred to as hallucinogenic. Psychedelic medicines are a group of substances, including chemicals, such as LSD, and plants used to treat multiple mental disorders, including resistant depression, opiate addiction, and panic disorder, among others. This medicine changes and enhances sensory perceptions, thought processes, and energy levels and facilitates favorable experiences. 

The Global psychedelic therapeutics market is proliferating owing to the increasing incidence of depression cases across the world. Additionally, changed lifestyles and quality of living are supporting the growth of psychedelic medicine market. In addition, the market is anticipated to expand lucratively as a result of the growing need for medicines to treat psychological drug dependency. On the other hand, a greater acceptance of non-therapeutic treatments over allopathic therapies and tight rules implemented by various governments to commercialize psychedelic medications may inhibit the market growth. 

In 2021, North America led the market. Major determinants, such as the increase in the frequency of depression and other mental diseases and the rapid advancement of research, are driving the market growth. The population's increased awareness of anxiety and mental health is anticipated to stimulate regional growth further. The Asia-Pacific region is anticipated to see a considerable growth rate over the projected period as a result of the growing awareness of mental diseases and the expansion of healthcare infrastructure.

The global psychedelic therapeutics market is segmented on the basis of Origin of Psychedelic Substance, Type of Psychedelic Substance, Target Therapeutic Area and region. Based on the Origin of Psychedelic Substance, the market is divided into Synthetic Substances and Natural Substances. On the basis of Type of Psychedelic Substance, the market is divided in to GHB, Ketamine, MDMA and Psilocybin. On the basis of Target Therapeutic Area, the market is divided into Depression and Anxiety Disorders, Pain Disorders, Sleep-Related Disorders and Trauma. Based on region, the market is studied across North America, Asia-Pacific, Europe, and LAMEA. Among that Europe held the largest share of the market, followed by America and Asia Pacific. On the other hand, North America is expected to dominate the market during the analysis of forecast period.

The key players of this market include Celon Pharma S.A., MAPS Public Benefit, MindMed, Janssen Pharmaceuticals, iX Biopharma Ltd, Jazz Pharmaceutical, Avadel, Pharmaceuticals plc, NeuroRx, Inc., Douglas Pharmaceuticals Limited, The Emmes, Company, LLC, CaaMTech, COMPASS Pathways plc, Eleusis Benefit Corporation, AWAKN Life Sciences Inc, Psilera Bioscience, Braxia Scientific Corp., Mindset Pharma, BetterLife Pharma, Cybin, CB Therapeutics, Numinus Wellness, Mydecine Innovations Group, Optimi Health, PharmaTher, Field Trip Health, ATAI Life Sciences, GH Research, Seelos Therapeutics, Small Pharma, Bright Minds Biosciences, Incannex Health, PsyBio Therapeutics, Universal Ibogaine, Levitee Labs, Mind Cure Health, Novamind, Clearmind Medicine, MYND Life Science, Wesana Health, Psyched Wellness, HAVN Life Sciences, Tryp Therapeutics, Psyence Group, Silo Pharma, Core One Labs, M2Bio Sciences, Neonmind Biosciences, Delic Corp, Nova Mentis Life Science, Beckley Psytech, Delix Therapeutics, Diamond Therapeutics, Tactogen, Psygen Labs Inc., Bexson Biomedical, Eleusis Biotech, Psilera Biosceince, Octarine Bio, Heading Health, MAPS Public Benefit Corporation (PBC), Aphrodite Health, Terran Biosciences, Mycrodose Therapeutics, Reset Pharma, Clerkenwell Health, Alvarius Pharmaceuticals, Ceruvia Lifesciences, and Other Prominent Player.

Chapter 1. Methodology and Scope

1.1. Research Methodology

1.2. Research Scope & Assumptions

Chapter 2. Executive Summary

Chapter 3. Global Psychedelic Therapeutics Market Snapshot

Chapter 4. Global Psychedelic Therapeutics Market Variables, Trends & Scope

4.1. Market Segmentation & Scope

4.2. Drivers

4.3. Challenges

4.4. Trends

4.5. Industry Analysis – Porter’s Five Forces Analysis

4.6. Competitive Landscape & Market Share Analysis

4.7. COVID 19 Impact on Pharmaceutical Industry

Chapter 5. Market Segmentation 1: Origin of Psychedelic Substance Estimates & Trend Analysis

5.1. Origin of Psychedelic Substance & Market Share, 2020 & 2028

5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2028 for the following Origin of Psychedelic Substance:

5.2.1. Synthetic Substances

5.2.2. Natural Substances

Chapter 6. Market Segmentation 1: By Type of Psychedelic Substance Estimates & Trend Analysis

6.1. By Type of Psychedelic Substance & Market Share, 2020 & 2028

6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2028 for the following By Type of Psychedelic Substance:

6.2.1. GHB

6.2.2. Ketamine

6.2.3. MDMA

6.2.4. Psilocybin

6.2.5. DMT

6.2.6. Ayahuasca

6.2.7. Lysergic acid diethylamide

6.2.8. Other

Chapter 7. Market Segmentation 2: Target Therapeutic Area Estimates & Trend Analysis

7.1. By Target Therapeutic Area & Market Share, 2020& 2028

7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2028 for the following By Target Therapeutic Area:

7.2.1. Depression and Anxiety Disorders

7.2.2. Pain Disorders

7.2.3. Sleep-Related Disorders

7.2.4. Trauma

7.2.5. Other

Chapter 8. Market Segmentation 3: Route of Administrations Estimates & Trend Analysis

8.1. Route of Administrations& Market Share, 2020 & 2028

8.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2028 for the following Route of Administrations:

8.2.1. Intranasal Therapies

8.2.2. Intravenous Therapies

8.2.3. Oral Therapies

8.2.4. Sublingual Therapies

Chapter 9. Psychedelic Therapeutics Market Segmentation 4: Regional Estimates & Trend Analysis

9.1. North America

9.1.1. North America Psychedelic Therapeutics Market revenue (US$ Million) estimates and forecasts by Origin of Psychedelic Substance, 2020-2028

9.1.2. North America Psychedelic Therapeutics Market revenue (US$ Million) estimates and forecasts by Type of Psychedelic Substance, 2020-2028

9.1.3. North America Psychedelic Therapeutics Market revenue (US$ Million) estimates and forecasts Target Therapeutic Area, 2020-2028

9.1.4. North America Psychedelic Therapeutics Market revenue (US$ Million) estimates and forecasts Route of Administrations, 2020-2028

9.1.5. North America Psychedelic Therapeutics Market revenue (US$ Million) estimates and forecasts by country, 2020-2028

9.2. Europe

9.2.1. Europe Psychedelic Therapeutics Market revenue (US$ Million) by Origin of Psychedelic Substance, 2020-2028

9.2.2. Europe Psychedelic Therapeutics Market revenue (US$ Million) by Type of Psychedelic Substance, 2020-2028

9.2.3. Europe Psychedelic Therapeutics Market revenue (US$ Million) Target Therapeutic Area, 2020-2028

9.2.4. Europe Psychedelic Therapeutics Market revenue (US$ Million) Route of Administrations, 2020-2028

9.2.5. Europe Psychedelic Therapeutics Market revenue (US$ Million) by country, 2020-2028

9.3. Asia Pacific

9.3.1. Asia Pacific Psychedelic Therapeutics Market revenue (US$ Million) by Origin of Psychedelic Substance, 2020-2028

9.3.2. Asia Pacific Psychedelic Therapeutics Market revenue (US$ Million) by Type of Psychedelic Substance, 2020-2028

9.3.3. Asia Pacific Psychedelic Therapeutics Market revenue (US$ Million) Target Therapeutic Area, 2020-2028

9.3.4. Asia Pacific Psychedelic Therapeutics Market revenue (US$ Million) Route of Administrations, 2020-2028

9.3.5. Asia Pacific Psychedelic Therapeutics Market revenue (US$ Million) by country, 2020-2028

9.4. Latin America

9.4.1. Latin America Psychedelic Therapeutics Market revenue (US$ Million) by Origin of Psychedelic Substance, (US$ Million)

9.4.2. Latin America Psychedelic Therapeutics Market revenue (US$ Million) by Type of Psychedelic Substance, (US$ Million)

9.4.3. Latin America Psychedelic Therapeutics Market revenue (US$ Million) Target Therapeutic Area, (US$ Million)

9.4.4. Latin America Psychedelic Therapeutics Market revenue (US$ Million) estimates and forecasts Route of Administrations, 2020-2028

9.4.5. Latin America Psychedelic Therapeutics Market revenue (US$ Million) by country, 2020-2028

9.5. Middle East & Africa

9.5.1. Middle East & Africa Psychedelic Therapeutics Market revenue (US$ Million) by Origin of Psychedelic Substance, (US$ Million)

9.5.2. Middle East & Africa Psychedelic Therapeutics Market revenue (US$ Million) by Type of Psychedelic Substance, (US$ Million)

9.5.3. Middle East & Africa Psychedelic Therapeutics Market revenue (US$ Million) Target Therapeutic Area, (US$ Million)

9.5.4. Middle East & Africa Psychedelic Therapeutics Market revenue (US$ Million) estimates and forecasts Route of Administrations, 2020-2028

9.5.5. Middle East & Africa Psychedelic Therapeutics Market revenue (US$ Million) by country, 2020-2028

Chapter 10. Competitive Landscape

10.1. Major Mergers and Acquisitions/Strategic Alliances

10.2. Company Profiles

10.2.1. Celon Pharma S.A.

10.2.2. MAPS Public Benefit

10.2.3. MindMed

10.2.4. Janssen Pharmaceuticals

10.2.5. iX Biopharma Ltd

10.2.6. Jazz Pharmaceutical

10.2.7. Avadel Pharmaceuticals plc

10.2.8. NeuroRx, Inc.

10.2.9. Douglas Pharmaceuticals Limited

10.2.10. The Emmes Company, LLC

10.2.11. CaaMTech

10.2.12. COMPASS Pathways plc

10.2.13. Eleusis Benefit Corporation

10.2.14. AWAKN Life Sciences Inc

10.2.15. Psilera Bioscience

10.2.16. Braxia Scientific Corp.

10.2.17. Mindset Pharma

10.2.18. BetterLife Pharma

10.2.19. Cybin

10.2.20. CB Therapeutics

10.2.21. Numinus Wellness

10.2.22. Mydecine Innovations Group

10.2.23. Optimi Health

10.2.24. PharmaTher

10.2.25. Field Trip Health

10.2.26. ATAI Life Sciences

10.2.27. GH Research

10.2.28. Seelos Therapeutics

10.2.29. Small Pharma

10.2.30. Bright Minds Biosciences

10.2.31. Incannex Health

10.2.32. PsyBio Therapeutics

10.2.33. Universal Ibogaine

10.2.34. Levitee Labs

10.2.35. Mind Cure Health

10.2.36. Novamind

10.2.37. Clearmind Medicine

10.2.38. MYND Life Science

10.2.39. Wesana Health

10.2.40. Psyched Wellness

10.2.41. HAVN Life Sciences

10.2.42. Tryp Therapeutics

10.2.43. Psyence Group

10.2.44. Silo Pharma

10.2.45. Core One Labs

10.2.46. M2Bio Sciences

10.2.47. Neonmind Biosciences

10.2.48. Delic Corp

10.2.49. Nova Mentis Life Science

10.2.50. Beckley Psytech

10.2.51. Delix Therapeutics

10.2.52. Diamond Therapeutics

10.2.53. Tactogen

10.2.54. Psygen Labs Inc.

10.2.55. Bexson Biomedical

10.2.56. Eleusis Biotech

10.2.57. Psilera Biosceince

10.2.58. Octarine Bio

10.2.59. Heading Health

10.2.60. MAPS Public Benefit Corporation (PBC)

10.2.61. Aphrodite Health

10.2.62. Terran Biosciences

10.2.63. Mycrodose Therapeutics

10.2.64. Reset Pharma

10.2.65. Clerkenwell Health

10.2.66. Alvarius Pharmaceuticals

10.2.67. Ceruvia Lifesciences

10.2.68. Other Prominent Player

Global Psychedelic Therapeutics Market Revenue (US$ Mn) by Origin of Psychedelic Substance

  • Synthetic Substances
  • Natural Substances

Global Psychedelic Therapeutics Market Revenue (US$ Mn) Based on Type of Psychedelic Substance

  • GHB
  • Ketamine
  • MDMA
  • Psilocybin
  • DMT
  • Ayahuasca
  • LSD
  • Other

Global Psychedelic Therapeutics Market Revenue (US$ Mn) Based on Target Therapeutic Area

  • Depression and Anxiety Disorders
  • Pain Disorders
  • Sleep-Related Disorders
  • Trauma
  • Other

Global Psychedelic Therapeutics Market Revenue (US$ Mn) Based on Region

Europe Psychedelic Therapeutics Market Revenue (US$ Mn) by Country

  • U.K.
  • Germany
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe

North America Psychedelic Therapeutics Market Revenue (US$ Mn) by Country

  • U.S.
  • Canada

Asia Pacific Psychedelic Therapeutics Market Revenue (US$ Mn) by Country

  • India
  • China
  • Japan
  • South Korea
  • Australia & New Zealand

Latin America Psychedelic Therapeutics Market Revenue (US$ Mn) by Country

  • Brazil
  • Mexico
  • Rest of Latin America

Middle East & Africa Psychedelic Therapeutics Market Revenue (US$ Mn) by Country

  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Major Qualitative Insights

  • Industry Overview
  • Future Trends in Psychedelic Therapeutics Market
  • Psychedelic Therapeutics Market Drivers and Challenges
  • Psychedelic Therapeutics Market Size and Forecast
  • Psychedelic Therapeutics Key News/Industry Activities
  • Major Mergers & Acquisition in Psychedelic Therapeutics Industry
  • Competitive Landscape
    • Celon Pharma S.A.
    • MAPS Public Benefit
    • MindMed
    • Janssen Pharmaceuticals
    • iX Biopharma Ltd
    • Jazz Pharmaceutical
    • Avadel Pharmaceuticals plc
    • NeuroRx, Inc.
    • Douglas Pharmaceuticals Limited
    • The Emmes Company, LLC
    • CaaMTech
    • COMPASS Pathways plc
    • Eleusis Benefit Corporation
    • AWAKN Life Sciences Inc
    • Psilera Bioscience
    • Braxia Scientific Corp.
    • Mindset Pharma
    • BetterLife Pharma
    • Cybin
    • CB Therapeutics
    • Numinus Wellness
    • Mydecine Innovations Group
    • Optimi Health
    • PharmaTher
    • Field Trip Health
    • ATAI Life Sciences
    • GH Research
    • Seelos Therapeutics
    • Small Pharma
    • Bright Minds Biosciences
    • Incannex Health
    • PsyBio Therapeutics
    • Universal Ibogaine
    • Levitee Labs
    • Mind Cure Health
    • Novamind
    • Clearmind Medicine
    • MYND Life Science
    • Wesana Health
    • Psyched Wellness
    • HAVN Life Sciences
    • Tryp Therapeutics
    • Psyence Group
    • Silo Pharma
    • Core One Labs
    • M2Bio Sciences
    • Neonmind Biosciences
    • Delic Corp
    • Nova Mentis Life Science
    • Beckley Psytech
    • Delix Therapeutics
    • Diamond Therapeutics
    • Tactogen
    • Psygen Labs Inc.
    • Bexson Biomedical
    • Eleusis Biotech
    • Psilera Biosceince
    • Octarine Bio
    • Heading Health
    • MAPS Public Benefit Corporation (PBC)
    • Aphrodite Health
    • Terran Biosciences
    • Mycrodose Therapeutics
    • Reset Pharma
    • Clerkenwell Health
    • Alvarius Pharmaceuticals
    • Ceruvia Lifesciences
    • Other Prominent Player

InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.

Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.

Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.

Secondary research

The secondary research sources that are typically mentioned to include, but are not limited to:

  • Company websites, financial reports, annual reports, investor presentations, broker reports, and SEC filings.
  • External and internal proprietary databases, regulatory databases, and relevant patent analysis
  • Statistical databases, National government documents, and market reports
  • Press releases, news articles, and webcasts specific to the companies operating in the market

The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista

Primary Research:

Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies

The contributors who typically take part in such a course include, but are not limited to: 

  • Industry participants: CEOs, CBO, CMO, VPs, marketing/ type managers, corporate strategy managers, and national sales managers, technical personnel, purchasing managers, resellers, and distributors.
  • Outside experts: Valuation experts, Investment bankers, research analysts specializing in specific markets
  • Key opinion leaders (KOLs) specializing in unique areas corresponding to various industry verticals
  • End-users: Vary mainly depending upon the market

Data Modeling and Analysis:

In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.

The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.

To know more about the research methodology used for this study, kindly contact us/click here.

Need Complete Report ?
Our Clients